N/A
Completed N=1,995
Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067)
Hepatitis C, Chronic
Source: ClinicalTrials.gov NCT00727259 ↗
Enrolled (actual)
1,995
Serious AEs
—
Results posted
Aug 2009
Primary outcomePrimary: Evaluation of the Satisfaction of the PegPen (PegIntron Preparation and Injection Easiness) Using a Patient Questionnaire Answered at 1 Month and 3 Months — 5.48; 5.91; 5.74; 6.08 satisfaction rating from 0-7
Summary
The current gold standard for treatment of chronic hepatitis C (CHC) patients is with pegylated interferon plus ribavirin. Drug administration accuracy and ease of use will definitely determine treatment effectiveness. This is the idea behind the development and usage of the PegPen. The goal of this study is to determine the satisfaction grade with this novel device.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Evaluation of the Satisfaction of the PegPen (PegIntron Preparation and Injection Easiness) Using a Patient Questionnaire Answered at 1 Month and 3 Months |
5.48; 5.91; 5.74; 6.08; 5.49; 5.84 | — |
Eligibility Criteria
Inclusion Criteria
- Adult patients with hepatitis C
Exclusion Criteria
- According to the products' labeling.
Data sourced from ClinicalTrials.gov (NCT00727259). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.